Merck & Co., Inc. (MRK) Shares Sold by HPM Partners LLC

HPM Partners LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRK) by 5.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 81,224 shares of the company’s stock after selling 4,675 shares during the quarter. HPM Partners LLC’s holdings in Merck & Co., Inc. were worth $4,930,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Nippon Life Global Investors Americas Inc. purchased a new position in shares of Merck & Co., Inc. in the 1st quarter worth approximately $11,079,000. Smith Salley & Associates grew its position in shares of Merck & Co., Inc. by 2.1% in the 1st quarter. Smith Salley & Associates now owns 96,117 shares of the company’s stock worth $5,235,000 after buying an additional 1,931 shares during the last quarter. Mcrae Capital Management Inc. grew its position in shares of Merck & Co., Inc. by 39.8% in the 1st quarter. Mcrae Capital Management Inc. now owns 7,783 shares of the company’s stock worth $424,000 after buying an additional 2,215 shares during the last quarter. Signature Financial Management Inc. grew its position in shares of Merck & Co., Inc. by 225.7% in the 1st quarter. Signature Financial Management Inc. now owns 30,903 shares of the company’s stock worth $1,684,000 after buying an additional 21,415 shares during the last quarter. Finally, Chicago Capital LLC purchased a new position in shares of Merck & Co., Inc. in the 1st quarter worth approximately $831,000. Institutional investors and hedge funds own 72.31% of the company’s stock.

A number of brokerages have recently issued reports on MRK. Citigroup set a $79.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, October 16th. Zacks Investment Research downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. ValuEngine raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday. Bank of America lifted their price objective on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Finally, Credit Suisse Group lifted their price objective on shares of Merck & Co., Inc. from $71.00 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday, October 11th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $70.24.

NYSE:MRK opened at $72.35 on Friday. The company has a market cap of $194.69 billion, a price-to-earnings ratio of 18.18, a P/E/G ratio of 2.23 and a beta of 0.81. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $72.89. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.61.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion for the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. Merck & Co., Inc.’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.01 EPS. On average, equities research analysts expect that Merck & Co., Inc. will post 4.28 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 2.65%. The ex-dividend date was Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 48.24%.

In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 279,850 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $72.07, for a total transaction of $20,168,789.50. Following the sale, the chairman now owns 971,800 shares of the company’s stock, valued at approximately $70,037,626. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the business’s stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total transaction of $14,825,915.00. Following the sale, the chairman now directly owns 938,788 shares in the company, valued at approximately $61,021,220. The disclosure for this sale can be found here. In the last three months, insiders have sold 929,360 shares of company stock worth $64,370,599. 0.32% of the stock is owned by insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: How do investors use RSI to grade stocks?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply